Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
FutureTech II Acquisition Corp ( (FTII) ) has issued an announcement.
Longevity Biomedical, Inc. and FutureTech II Acquisition Corp. have announced a definitive business combination aimed at creating a Nasdaq-listed biopharmaceutical giant concentrating on extending human health and longevity. The new entity will focus on developing innovative therapies across various fields such as ophthalmology, cardiovascular disease, and soft tissue reconstruction, with several near-term clinical milestones anticipated. Leveraging a seasoned management team, the combined company aspires to be a market consolidator, offering advanced healthcare solutions to meet the increasing needs of an aging global population. The transaction is expected to close in the fourth quarter of 2024, with the combined company trading under the ticker symbol “LBIO”.
For detailed information about FTII stock, go to TipRanks’ Stock Analysis page.